Getting approved for Mounjaro: what the decision actually involves

The eligibility threshold: where your BMI sits and what else counts

The UK licence for tirzepatide covers adults with a BMI of 30 or above, or 27 or above when at least one weight-related condition is present. Conditions that typically satisfy that second criterion include type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease, though the prescriber considers each case individually rather than ticking a fixed checklist.

If you are unsure where your BMI places you, the NHS BMI calculator gives you a starting point before your consultation. Bear in mind that UK guidance applies thresholds roughly 2.5 kg/m² lower for certain ethnic backgrounds, so someone who reads as just below the headline figure may still qualify, worth raising with your prescriber directly.

Age is a firm line: Mounjaro is not licensed for anyone under 18, and a prescriber cannot issue it regardless of BMI. If you want the detail on minimum age requirements, this page covers the age rules for Mounjaro in full. Equally, the target body weight that places you in scope is worth understanding before you apply, our page on the weight thresholds goes through the numbers clearly.

What a prescriber is actually looking for beyond the numbers

Meeting the BMI threshold opens the door; it does not walk you through it. Your prescriber is also assessing whether Mounjaro is the right medicine for you specifically, which means looking at a broader set of factors.

Certain conditions affect whether tirzepatide can be prescribed safely. A personal or family history of medullary thyroid carcinoma or MEN2 syndrome, a history of pancreatitis, and some gastrointestinal conditions all require careful consideration. Pregnancy, breastfeeding and actively trying to conceive are situations where the medicine is not recommended. Your prescriber will also review your current medications: oral contraceptives, for instance, may need a supplementary non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide can slow gastric emptying in ways that affect pill absorption. NHS England's guidance on weight-management injections covers this and other practical considerations in detail.

If you are already on treatment elsewhere and looking to transfer, that process has its own requirements, evidence of your current dose and recent weight verification, reviewed before any supply continues. The guide to switching from Saxenda to Mounjaro gives a sense of how that assessment works in practice.

How the decision is reached at a private pharmacy like nume

The consultation is where the clinical decision happens. At nume, it starts with a free health questionnaire covering your BMI, medical history, current medicines and weight-management goals. That information goes to a prescriber (not software, not an automated filter) who reviews it and either approves treatment, asks follow-up questions, or declines and explains why.

Identity and weight are both verified: a photo ID check and live video weight confirmation are standard parts of the process. This matters because accurate weight determines both eligibility and the starting dose. Speaking of which, Mounjaro always begins at 2.5 mg (a tolerability dose that gives your system time to adjust) before your prescriber considers any increase, and each step up requires its own clinical sign-off.

On the practical side: orders placed by midday on a weekday are dispatched the same day once approved, arriving via tracked DPD the next working day. If your payday falls at the end of the month and you want to time your first order for a Monday, that rhythm works fine, the process is the same whenever you start. There are no subscriptions; every repeat is clinically reviewed before it goes out. You can read more about what the full consultation involves on the how to apply for Mounjaro page, and the preparation guide is worth a look before you begin.

What happens if you are not approved, and what to ask next

A prescriber declining to issue a prescription is not a closed door; it is clinical feedback. The most common reasons are that BMI falls outside the licensed range, a contraindicated condition is present, or information provided during the consultation needs clarification. In some cases a conversation with your GP first is the right next step, particularly if your weight-related health conditions are managed by your GP practice.

For context on where Mounjaro sits relative to other options, the weight-loss treatments overview sets out the licensed landscape. If you are comparing tirzepatide to other agents, the retatrutide vs Mounjaro comparison gives a clear evidence-based picture of how the options differ. And if cost is part of your thinking, the honest breakdown on the Mounjaro price comparison page explains what transparent private pricing actually includes.

Once you have a clear sense of where you stand, the practical next step is a consultation with a qualified prescriber. Start your free consultation with nume, a prescriber will review your details the same day and give you a straight answer.